TY - JOUR T1 - Long term follow up after bronchoscopic lung volume reduction valve treatment for emphysema JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00235-2022 SP - 00235-2022 AU - Jorine E. Hartman AU - Karin Klooster AU - T. David Koster AU - Nick H. T. ten Hacken AU - Marlies van Dijk AU - Dirk-Jan Slebos Y1 - 2022/01/01 UR - http://openres.ersjournals.com/content/early/2022/08/18/23120541.00235-2022.abstract N2 - Background Multiple studies have shown that patients with severe emphysema can significantly benefit from the bronchoscopic lung volume reduction treatment with endobronchial valves (EBV) up to 1 year after treatment. However, hardly any data exists on longer term follow-up, especially on quality of life. Our aim was to investigate the long term follow-up after EBV treatment up to 3 years including quality of life in a real life routine clinical setting.Methods We retrospectively included patients who underwent EBV treatment in our hospital at least 3 years ago. Patients were invited for annual visits to our hospital and spirometry, bodyplethysmography, 6-min walk distance test (6 MWD) and SGRQ-questionnaire were performed during these visits.Results At one, two and three years of follow-up, data was available from 189, 146 and 112 patients, respectively. FEV1, RV and SGRQ total score significantly improved as compared to baseline up to 3 years after treatment and 6MWD up to 2 years. In general, the magnitude of the improvements gradually decreased over time.Conclusion Our results show that patients can benefit at least up to three years after the EBV treatment. For the first time we found that patients can also benefit in terms of quality of life in the long term which is an important outcome for these group of patients with end-stage COPD.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflicts of interest statement: DJS reports: Grants or contracts from PulmonX Corp., USA, PneumRx/BTG/Boston Sc. USA, FreeFlowMedical, USA and Nuvaira, USA (PI and advisor to institution); consulting fees from PulmonX Corp., USA, PneumRx, USA and Nuvaira, USA; payment or honoraria for lectures from PulmonX Corp., USA, PneumRx, USA and Nuvaira, USA; support for attending meetings and/or travel from PulmonX Corp., USA, PneumRx, USA and Nuvaira, USA, Receipt of study material and medical devices to institution from PulmonX Corp., USA, PneumRx, USA and Nuvaira, USA. KK reports payment or honoraria for lectures from PulmonX and Boehringer. All other authors have nothing to disclose. ER -